Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Equity Average (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Equity Average for 3 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 85.64% to $22.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Dec 2025, down 85.64% year-over-year, with the annual reading at $70.8 million for FY2025, 20.05% down from the prior year.
  • Equity Average for Q4 2025 was $22.4 million at Inhibrx Biosciences, down from $52.7 million in the prior quarter.
  • The five-year high for Equity Average was $198.9 million in Q3 2024, with the low at $22.4 million in Q4 2025.
  • Average Equity Average over 3 years is $90.8 million, with a median of $84.0 million recorded in 2023.
  • Peak annual rise in Equity Average hit 314.06% in 2025, while the deepest fall reached 85.64% in 2025.
  • Over 3 years, Equity Average stood at $86.5 million in 2023, then skyrocketed by 80.27% to $156.0 million in 2024, then plummeted by 85.64% to $22.4 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $22.4 million, $52.7 million, and $81.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.